The Establishment of Gene Therapy with and Gene Expression Regulation of Adenoviral Vector Serotype 35
| Project/Area Number |
21592242
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
MORI Keisuke 埼玉医科大学, 医学部, 准教授 (90251090)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 眼細胞生物学 / 遺伝子治療 / アデノウイルスベクター / 血清型 / 血管新生 / 神経保護 |
|---|
| Research Abstract |
Adenoviral vectors(Ad) have several attractive properties, including high transduction efficiency, transduction of a wide spectrum of dividing and non-dividing cells and absence of random integration into the host genome. Two phase I clinical trials using adenoviral vector have successfully been conducted in 2005 and 2006, one in a pediatric population, and the other in an elderly population. However, since Ad serotype 5 is highly prevalent in the human population, many individuals have been exposed to Ad5 and subsequently, have generated a dose-dependent neutralizing antibody response. This antibody response toAd5 is thought by many to contribute to a shorter duration of transgene expression, which is considered to be a disadvantage of adenoviral vector therapy. In this study we provided the evidence that Ad35 and Ad28 delivered subretinally gave prolonged gene expression as compared to conventional Ad5. These facts indicate the basis for the development of therapeutic protein agents that are applicable to the pathogenesis and treatment of ocular diseases such as age-related macular degeneration.
|
Report
(4 results)
Research Products
(18 results)
-
[Journal Article] Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration2011
Author(s)
Tsuchihashi T, Mori K, Horie-Inoue K, Gehlbach PL, Kabasawa S, Takita H, Kueyama K, Okazaki Y, Inoue S, Awata T, Katayama S, Yoneya S
-
Journal Title
Ophthalmology
Volume: 118
Pages: 93-100
Related Report
Peer Reviewed
-
-
[Journal Article] Genome-wide association study identifies two susceptibility loci for exudative age-related macular degeneration in the Japanese population2011
Author(s)
Arakawa S, Takahashi A, Ashikawa K, Hosono N, Aoi T, Yasuda M, Oshima Y, Yoshida S, Enaida H, Tsuchihashi T, Mori K, Honda S, Negi A, Arakawa A, Kadonosono K, Kiyohara Y, Kamatani N, Nakamura Y, Ishibashi T, Kubo M
-
Journal Title
Nat Genet
Volume: 43
Pages: 1001-4
Related Report
Peer Reviewed
-
[Journal Article] Association of Elastin Gene Polymorphism to Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy2011
Author(s)
Yamashiro K, Mori K, Nakata I, Tsuchihashi T, Horie-Inoue K, Nakanishi H, Tsujikawa A, Saito M, Iida T, Yamada R, Matsuda F, Inoue S, Awata T, Yoneya S, Yoshimura N
-
Journal Title
Invest Ophthalmol Vis Sci
Volume: 52
Pages: 8780-4
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Presentation] Comparison of Transduction Efficiency and Intraocular Localization of Reporter Genes After Intravitreal and Subretinal Injection of the Adenovirus Vectors of Serotypes 5, 28, and 35 With Fiber Modifications2010
Author(s)
K. Ueyama, K. Mori, M. M. Hamilton, H. Omata, P. L. Gehlbach, L. L. Wei, S. Yoneya.
Organizer
Association for Research in Vision and Ophthalmology 2010
Place of Presentation
Fort Lauderdale, FL, USA
Year and Date
2010-05-06
Related Report
-
-
-
-
